醛糖还原酶抑制剂预防糖尿病相关视网膜微血管病变

Prevention of diabetes-related retinal microangiopathy with aldose reductase inhibitors.

作者信息

Robison W G

机构信息

Laboratory of Mechanisms of Ocular Diseases, National Eye Institute, Bethesda, Maryland.

出版信息

Adv Exp Med Biol. 1988;246:365-72. doi: 10.1007/978-1-4684-5616-5_45.

DOI:10.1007/978-1-4684-5616-5_45

PMID:3150650

Abstract

Before any clinical signs of diabetic retinopathy can be detected, two major histopathological lesions occur in the walls of retinal capillaries: basement membrane thickening; and loss of intramural pericytes (mural cells). A decrease in the number of pericyte to endothelial cell junctions also occurs under diabetic conditions and may result in subsequent proliferation of endothelial cells and microaneurysm formation. Aldose reductase inhibitors prevent all these diabetic microangiopathies of the retina in animal models of diabetes and are presently being tested in clinical trials on diabetic retinopathy. Utilization of aldose reductase inhibitors is a novel approach which would potentially provide a very effective diabetic therapy to be used in addition to insulin.

摘要

在检测到糖尿病视网膜病变的任何临床症状之前，视网膜毛细血管壁会出现两种主要的组织病理学病变：基底膜增厚；以及壁内周细胞（壁细胞）丢失。在糖尿病状态下，周细胞与内皮细胞连接的数量也会减少，这可能导致内皮细胞随后增殖并形成微动脉瘤。在糖尿病动物模型中，醛糖还原酶抑制剂可预防所有这些视网膜糖尿病微血管病变，目前正在针对糖尿病视网膜病变进行临床试验。使用醛糖还原酶抑制剂是一种新方法，有可能提供一种非常有效的糖尿病治疗方法，可与胰岛素一起使用。